RESUMEN
Increased postprandial lipemia is a cardiovascular disease (CVD) risk factor. Carob fruit extract (CFE) contains condensed tannins, and their intake has been inversely related to CVD. The objective was to evaluate the in vitro pancreatic lipase activity in the presence of CFE and the in vivo effect of CFE on postprandial lipemia of healthy Wistar rats in acute and subchronic digestibility studies and to relate it with changes in fat digestion and absorption. CFE significantly reduced pancreatic lipase activity. A peak delay and a dose-dependent decrease in plasma triglyceride and cholesterol areas under the curve were observed, effects that increased after the subchronic treatment. The levels of nondigested, nonabsorbed triglycerides of the remaining intestinal lumen fat were significantly higher in the maximum dose of CFE administrated versus the control ( P < 0.05). This study demonstrates for the first time the hypolipemic properties of CFE from the first administration, modifying postprandial lipemia by reducing the extents of fat digestion and absorption.
Asunto(s)
Fabaceae/química , Grasas/metabolismo , Hiperlipidemias/tratamiento farmacológico , Hiperlipidemias/metabolismo , Extractos Vegetales/administración & dosificación , Animales , Frutas/química , Humanos , Lipasa/metabolismo , Masculino , Periodo Posprandial , Ratas , Ratas Wistar , Triglicéridos/metabolismoRESUMEN
ANTECEDENTS: Commercialized like dietetic supplement, chromium picolinate has been promoted to favour the increase of muscle mass and the loss of weight, due to its' effect on the action of insulin. OBJECTIVE: To evaluate the effect of supplementation of the diet with chromium (500 microg/kg) in the form of chromium picolinate (CrPic) (12 days) on growth and protein turnover in rats at different growth stages (infantile and puberal). RESULTS AND DISCUSSION: No significant effect of CrPic on bodyweight gain, feed intake and feed conversion rate was observed at any of the stages of development studied. CrPic seems to increase the muscle mass, either by stimulating protein anabolism due to the involution of the insulin by chromium, or by reducing protein catabolism. CONCLUSIONS: Since the use of chromium picolinate could jeopardize the correct renal function and its' beneficial effects are not evident, it should always be consumed with caution.
Asunto(s)
Crecimiento y Desarrollo/efectos de los fármacos , Ácidos Picolínicos/farmacología , Factores de Edad , Animales , Suplementos Dietéticos , Masculino , Proteínas/efectos de los fármacos , Proteínas/metabolismo , Ratas , Ratas WistarRESUMEN
El cromo, un popular pero controvertido micronutriente, puede incrementar el músculo esquelético cuando se administra en forma de suplemento, presumiblemente debido a su acción sobre la insulina. Este estudio se ha realizado con el fin de evaluar los efectos de tres niveles diferentes de cromo dietético (100, 200 y 500 µg/Kg) en forma de picolinato de cromo (Pic-Cr) sobre el crecimiento y utilización proteica de ratas en edad puberal, durante doce días. La suplementación de la dieta de estos animales no ejerce un efecto significativo sobre el crecimiento, ingesta de alimento, aprovechamiento de alimento y utilización de nutrientes, especialmente de proteínas. El efecto del PicCr sobre la masa corporal, además de no ser significativo, sería totalmente marginal y atribuible, más que a su acción sobre la activación de la insulina, a su capacidad para disminuir el catabolismo proteico. El consumo de este compuesto, además, podría comprometer el buen funcionamiento renal, por lo que debería realizarse con mucha precaución (AU)
Asunto(s)
Animales , Ratas , Compuestos de Cromo/administración & dosificación , Crecimiento/fisiología , Micronutrientes/farmacología , Micronutrientes , Dieta/métodos , Dieta , Alimentos Fortificados , Alimentos Fortificados/efectos adversos , Picolinas/administración & dosificación , Peso Corporal/fisiología , Peso Corporal , Catepsinas/administración & dosificación , Enfermedades Renales/complicacionesRESUMEN
This study aimed (i) to design an in vivo model to study fat digestibility, and (ii) to apply this design to test the in vivo digestibility of a highly thermoxidized olive oil. True digestibility of unheated olive oil was tested 2, 4, 6, and 7 h after administering 1 g of olive oil/100 g body weight to young adult Wistar rats by means of esophageal probes. Remaining gastrointestinal lumen fat showed an inversely linear relationship (r= -0.9932; P < 0.001) with the length of the experiment. A 4-h test was considered adequate because after this period, half of the oil administer still remains in the lumen, making it possible to accurately measure the different nondigested, nonabsorbed thermoxidized compounds. In a second experiment, fresh olive oil (3.6 mg polar content/100 mg oil) was heated at 180 degrees C for 50 h in the presence of air; the polar content in this oil rose to 46.0 mg/100 mg oil. After 4 h, the true digestibility coefficient of 50-h heated olive oil did not significantly change, although it tended to decrease (24%) with respect to the unheated oil. Silica gel column chromatography and high-performance size exclusion chromatography were used to quantify nonthermoxidized and thermoxidized products present in the oils and in the gastrointestinal lumen after these test periods. True digestibility of the different thermoxidized compounds from the heated oil was 30-40%, whereas that of thermoxidized compounds from the fresh oil was much higher (approximately 80%). Nonoxidized triacylglycerol hydrolysis was negatively affected by the presence of large amounts of thermoxidized compounds. The present proposed model seems to be a useful tool for the study of thermoxidized oils. Data also show that thermoxidized compounds from abused olive oil are poorly but actively hydrolyzed and absorbed in vivo.
Asunto(s)
Cromatografía en Gel , Cromatografía Líquida de Alta Presión , Digestión , Calor , Aceites de Plantas/metabolismo , Polímeros , Animales , Diglicéridos/metabolismo , Dimerización , Ácidos Grasos no Esterificados/metabolismo , Hidrólisis , Masculino , Modelos Biológicos , Aceite de Oliva , Oxidación-Reducción , Ratas , Ratas Wistar , Factores de Tiempo , Triglicéridos/metabolismoRESUMEN
We compared CSF and serum selenium levels, measured by atomic absorption spectrophotometry, in 27 patients with Alzheimer's disease (AD) (13 females, 14 males, mean +/- SD age 73.6 +/- 7.4 years) without major clinical signs of undernutrition, and 34 matched controls (18 females, 16 males, mean +/- SD age 70.7 +/- 7.8 years). CSF and serum selenium levels did not differ significantly between AD-patient (11.4 +/- 7.8 ng/ml and 28.5 +/- 13.0 ng/ml, respectively) and control groups (13.3 +/- 7.0 ng/ml and 22.5 +/- 17.5 ng/ml). These values were not correlated with age, age at onset, duration of the disease, and scores of the MiniMental State Examination in the AD group. Weight and body mass index were significantly lower in AD patients than in controls. These results suggest that CSF selenium concentrations are apparently unrelated with the reported oxidative stress processes in patients with AD.
Asunto(s)
Enfermedad de Alzheimer/líquido cefalorraquídeo , Selenio/líquido cefalorraquídeo , Anciano , Anciano de 80 o más Años , Enfermedad de Alzheimer/sangre , Femenino , Humanos , Masculino , Concentración Osmolar , Valores de Referencia , Espectrofotometría Atómica , Vitamina A/sangreRESUMEN
We compared CSF and serum levels of selenium and chromium, measured by atomic absorption spectrophotometry, in 28 patients with Parkinson's disease (PD) and 43 matched controls. The CSF and serum levels of these trace metals did not differ significantly between PD patients and controls. CSF selenium and chromium levels were not correlated with age, age at onset, duration of the disease, scores of the Unified Parkinson Disease Rating Scale of the Hoehn and Yahr staging in the PD group. Although antiparkinsonian therapy did not influence significantly the CSF levels of selenium, PD patients not treated with levodopa had significantly higher CSF selenium levels than controls (p < 0.01). It is possible that increased CSF selenium levels could indicate an attempt of protection against oxidative stress. The normality of CSF and serum chromium levels suggest that these values are not related with the risk for PD.